Inclusion Criteria:

• Subjects with functional class (CCS) III or IV angina.
• Subjects who have attempted "best" medical therapy without control of symptoms.
• All subjects must have a recent coronary angiogram (within the last 3 months).
• Clinical signs and symptoms of clinically significant ischemia on nuclear perfusion imaging.
• Subjects must be able to complete a minimum of 1 minute but no more than 6 minutes of the Standard Bruce Protocol.
• Subject experiences angina during the baseline exercise tolerance test.
• Subjects must either be no longer capable of reproduction or taking acceptable measures to prevent reproduction during the study.
• Normal renal function.
• Normal liver function.
• Normal blood count.

Angiographic Inclusions:

• Total occlusion of an epicardial coronary artery.
• Candidates at high risk for percutaneous coronary angioplasty of treatment zone(s) based upon clinical or anatomic considerations including but not limited to the following: diabetes, congestive heart failure (severe right heart failure, NYHA class III or IV), left main disease, pulmonary hypertension, severe proximal vessel tortuosity, severe bendpoint obstructions, diffuse disease (>2 cm in length), small vessel (<2 mm reference diameter), stenosis which are either diffuse (>2 cm in length) or distal, incessant restenosis lesions, unfavorable bifurcation stenosis, and degenerated or thrombosed saphenous vein grafts.

Exclusion Criteria:

• Predominant congestive heart failure symptoms.
• Patients who have been hospitalized with a primary diagnosis of CHF in the prior 6 months.
• Patients who have had diuretics added to their medical regimen or an increase in diuretic dosage for signs or symptoms of CHF in the past 6 months.
• Patients with a left ventricular ejection fraction of less than 25% as determined by transthoracic echocardiography.
• Patients with physical findings consistent with ongoing uncontrolled CHF.
• Myocardial infarction within 30 days of treatment.
• Successful coronary revascularization procedures within 3 months of study enrollment.
• Documented stroke or transient ischemic attack (TIA) within 60 days of study enrollment.
• History of severe aortic stenosis or insufficiency; severe mitral stenosis; or severe mitral insufficiency.
• Severe co-morbidity associated with a reduction in life expectancy of less than 1 year.
• Subjects with PT, PTT or platelet counts greater than the upper limit of normal and those with a hematocrit <35%.
• Subjects with uncontrolled hypertension.
• Currently enrolled in another investigational device or drug trial (IDE or IND) that has not completed the required follow-up period.
• History of alcohol or drug abuse within 3 months of screening.
• Joint or peripheral vascular disease that severely limits treadmill walking.
• Chronic obstructive pulmonary disease that severely limits walking or FEV1.0<30% predicted.
• Subjects who are pregnant or lactating.
• Males and females who are capable of reproduction and will not take acceptable measures to prevent reproduction during the study.
• Subjects who test positive for HIV, hepatitis B or hepatitis C, have a chronic inflammatory disease, autoimmune disease or are on chronic immunosuppressive medications.
• Subjects with a known hypersensitivity to E. coli-derived proteins.
• Subjects with evidence (clinical, laboratory, or imaging) of cancer recurrence within the past 5 years (other than non-melanoma skin cancer or in situ cervical carcinoma).